Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 47

Sort by

Sort Order Select

Journal Articles

IPSS-m outperforms IPSS-R in younger adults with Myelodysplastic Syndromes: A retrospective age-stratified analysis

Jinjun Yang, Ya Zhang, Yu Wu

Blood (2025) 146 (Supplement 1): 7391.

https://doi.org/10.1182/blood-2025-7391

Published: 2025

Journal Articles

Erythrocyte membrane-camouflaged JAK1 inhibitor for the treatment of hemophagocytic lymphohistiocytosis

Mengran Chen, Ying Qu, Yu Wu

Blood (2025) 146 (Supplement 1): 2991.

https://doi.org/10.1182/blood-2025-2991

Published: 2025

Journal Articles

Results of POLARIS-1, a global Phase 3 study (Part A): Olverembatinib combined with low-intensity chemotherapy in patients with newly diagnosed (ND) Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL)

Blood (2025) 146 (Supplement 1): 1574.

https://doi.org/10.1182/blood-2025-1574

Published: 2025

Journal Articles

Azacitidine and luspatercept metronomic therapy for intermediate- to high-risk myelodysplastic syndrome: A prospective single-center phase II clinical trial

Chenlu Yang, Qing Li, Yu Wu

Blood (2025) 146 (Supplement 1): 5625.

https://doi.org/10.1182/blood-2025-5625

Published: 2025

Journal Articles

Chidamide-based epigenetic therapy for relapsed/refractory Acute Myeloid Leukemia

Qing Li, Yu Wu

Blood (2025) 146 (Supplement 1): 6982.

https://doi.org/10.1182/blood-2025-6982

Published: 2025

Journal Articles

Early efficacy and safety of luspatercept in myelofibrosis-associated anemia: A clinical study with biomarker exploration

Junyao Huang, Ting Niu, Ling Pan, Huanling Zhu, Yu WU, Yunfan Yang

Blood (2025) 146 (Supplement 1): 1116.

https://doi.org/10.1182/blood-2025-1116

Published: 2025

Journal Articles

Real-world safety profile of PD-1 inhibitors in Epstein–Barr Virus–Associated lymphoproliferative disorders: A retrospective analysis from west China hospital

Yang Dai, Pengpeng Liu, Yu Wu, Ting Liu, Ting Niu, Manikanta Boda

Blood (2025) 146 (Supplement 1): 3008.

https://doi.org/10.1182/blood-2025-3008

Published: 2025

Journal Articles

Venetoclax-based regimens are non-inferior to chemotherapy in core binding factor AML, including AML1-ETO

Yu Wu, Lei Zhao, Yufei Yang, Xinrong Xiang

Blood (2025) 146 (Supplement 1): 6965.

https://doi.org/10.1182/blood-2025-6965

Published: 2025

Journal Articles

The venetoclax conundrum: Therapeutic drug monitoring of venetoclax: Correlation with response in Acute Myeloid Leukemia？

Yufei Yang, Lei Zhao, Yu Wu

Blood (2025) 146 (Supplement 1): 5234.

https://doi.org/10.1182/blood-2025-5234

Published: 2025

Journal Articles

A clinical study on the Efficacy and safety of luspatercept in Chinese patients with non-transfusion-dependent β-thalassemia

He Li, Ting Niu, XINMEI YU, CHIYI WANG, LEI JIA, JUAN QIU, Huanling Zhu, Ling Pan, Yu WU, JING TAN, CHUNRONG MA, YING YUAN, Tian Dong, JIHENG LIU, GUOYU HU, HONGYUN XING, Jian Xiao, Chuan He

Blood (2025) 146 (Supplement 1): 1142.

https://doi.org/10.1182/blood-2025-1142

Published: 2025

Journal Articles

Aberrant activation of clpp exerts multifaceted anti-AML activity beyond tumor cells

Xinrong Xiang, Lei Zhao, Yu Wu

Blood (2025) 146 (Supplement 1): 3289.

https://doi.org/10.1182/blood-2025-3289

Published: 2025

Journal Articles

Orelabrutinib-Bruton Tyrosine Kinase Inhibitor-Based Regimens in the Treatment of Marginal Zone Lymphoma: A Retrospective Study

He LI, Jiazhuo Liu, Yuhui Chen, Pazilaiti Tuohuti, Yutong Wang, Xinzhu Tang, Bing Xiang, Yongqian Jia, Yu Wu, Yun Tang, Yong Guo, Jie Wang, Yuhuan Zheng, Yu Liu, Ting Niu

Blood (2024) 144 (Supplement 1): 6308.

https://doi.org/10.1182/blood-2024-206464

Published: 2024

Journal Articles

Genomic Proximity Mapping (GPM): Evaluation of a Next Generation Cytogenomic Assay for Improved Risk Stratification in Acute Myeloid Leukemia

Blood (2024) 144 (Supplement 1): 6157.

https://doi.org/10.1182/blood-2024-211570

Published: 2024

Journal Articles

An Erythrocyte-Based Delivery Platform for Leukemia Treatment

Mengran Chen, Lei Zhao, Ying Qu, Yu Wu

Blood (2024) 144 (Supplement 1): 4027.

https://doi.org/10.1182/blood-2024-208015

Published: 2024

Journal Articles

Deciphering Clonal Evolution of Immunoglobulin Heavy Chain Locus Enhances Next-Generation Sequencing-Based Measurable Residual Disease Detection in Adult B-Acute Lymphoblastic Leukemia

Yang Dai, Bei Yu, Jie Zhang, Yu Wu, Zhidong Yang, Na Wang, Tong Chen, Libo Hu, Wanqiu Yang, Shiang Huang, Ting Liu, Xiaofei Ye

Blood (2024) 144 (Supplement 1): 2840.

https://doi.org/10.1182/blood-2024-204493

Published: 2024

Journal Articles

Venetoclax Plus Dexamethasone As First-Line Treatment for t(11; 14) Light-Chain Amyloidosis: Preliminary Result of a Phase II Prospective, Multicenter, Single-Arm Study

Kaini Shen, Ai Guan, Yu Wu, Chunyan Sun, Liye Zhong, Jun Luo, Jian Li

Blood (2024) 144 (Supplement 1): 893.

https://doi.org/10.1182/blood-2024-204346

Published: 2024

Journal Articles

Association between Venetoclax Plasma Concentrations and Treatment Response of Acute Myeloid Leukemia

Yufei Yang, Lei Zhao, Jinjun Yang, Xuefeng Li, Yu Wu

Blood (2024) 144 (Supplement 1): 6039.

https://doi.org/10.1182/blood-2024-205468

Published: 2024

Journal Articles

Nirmatrelvir/Ritonavir Reduces Infection Duration in Hospitalized Hematological Malignancies Patients with Mild-to-Moderate COVID-19: A Retrospective Study

Hongbin Yu, Tian Chen, Jiawei Li, Xin Zhang, Yu Wu

Blood (2024) 144 (Supplement 1): 5955.

https://doi.org/10.1182/blood-2024-207488

Published: 2024

Journal Articles

Myelomonocytic/Monocytic Subtypes Are More Resistant to Venetoclax-Based Therapy in Acute Myeloid Leukemia Patients: A Monocentric, Real-Life Retrospective Study

Lei Zhao, Jinjun Yang, Yu Wu, Xinrong Xiang

Blood (2023) 142 (Supplement 1): 4266.

https://doi.org/10.1182/blood-2023-185954

Published: 2023

Journal Articles

Changes in Immune-Related Indicators in Patients with Hematopoietic Abnormalities and Their Impact on Clinical Symptoms

Mengran Chen, Lei Zhao, Jinjun Yang, Yu Wu

Blood (2023) 142 (Supplement 1): 6502.

https://doi.org/10.1182/blood-2023-191057

Published: 2023

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

IPSS-m outperforms IPSS-R in younger adults with Myelodysplastic Syndromes: A retrospective age-stratified analysis

Erythrocyte membrane-camouflaged JAK1 inhibitor for the treatment of hemophagocytic lymphohistiocytosis

Results of POLARIS-1, a global Phase 3 study (Part A): Olverembatinib combined with low-intensity chemotherapy in patients with newly diagnosed (ND) Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL)

Azacitidine and luspatercept metronomic therapy for intermediate- to high-risk myelodysplastic syndrome: A prospective single-center phase II clinical trial

Chidamide-based epigenetic therapy for relapsed/refractory Acute Myeloid Leukemia

Early efficacy and safety of luspatercept in myelofibrosis-associated anemia: A clinical study with biomarker exploration

Real-world safety profile of PD-1 inhibitors in Epstein–Barr Virus–Associated lymphoproliferative disorders: A retrospective analysis from west China hospital

Venetoclax-based regimens are non-inferior to chemotherapy in core binding factor AML, including AML1-ETO

The venetoclax conundrum: Therapeutic drug monitoring of venetoclax: Correlation with response in Acute Myeloid Leukemia？

A clinical study on the Efficacy and safety of luspatercept in Chinese patients with non-transfusion-dependent β-thalassemia

Aberrant activation of clpp exerts multifaceted anti-AML activity beyond tumor cells

Orelabrutinib-Bruton Tyrosine Kinase Inhibitor-Based Regimens in the Treatment of Marginal Zone Lymphoma: A Retrospective Study

Genomic Proximity Mapping (GPM): Evaluation of a Next Generation Cytogenomic Assay for Improved Risk Stratification in Acute Myeloid Leukemia

An Erythrocyte-Based Delivery Platform for Leukemia Treatment

Deciphering Clonal Evolution of Immunoglobulin Heavy Chain Locus Enhances Next-Generation Sequencing-Based Measurable Residual Disease Detection in Adult B-Acute Lymphoblastic Leukemia

Venetoclax Plus Dexamethasone As First-Line Treatment for t(11; 14) Light-Chain Amyloidosis: Preliminary Result of a Phase II Prospective, Multicenter, Single-Arm Study

Association between Venetoclax Plasma Concentrations and Treatment Response of Acute Myeloid Leukemia

Nirmatrelvir/Ritonavir Reduces Infection Duration in Hospitalized Hematological Malignancies Patients with Mild-to-Moderate COVID-19: A Retrospective Study

Myelomonocytic/Monocytic Subtypes Are More Resistant to Venetoclax-Based Therapy in Acute Myeloid Leukemia Patients: A Monocentric, Real-Life Retrospective Study

Changes in Immune-Related Indicators in Patients with Hematopoietic Abnormalities and Their Impact on Clinical Symptoms

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only